Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9822895 | 0.77 | P2RX7 (0.40) | SMN1; SMN2CD44LMNATSHRALDH1A1 | |
| SCHEMBL19463315 | 0.77 | KCNN4 (0.40) | SMN1; SMN2CD44LMNACYP3A4TSHR | |
| SCHEMBL12500994 | 0.73 | P2RX7 (0.54) | LMNATSHRALDH1A1KDM4EP2RX7 | |
| SCHEMBL15698665 | 0.72 | TYK2 (0.41) | SMN1; SMN2LMNATSHRNPSR1P2RX7 | |
| SCHEMBL22786993 | 0.72 | KCNN4 (0.47) | SMN1; SMN2LMNATSHRALDH1A1NPSR1 | |
| SCHEMBL30839716 | 0.71 | CD44 (0.65) | SMN1; SMN2CD44DPP4CYP3A4TDP1 | |
| SCHEMBL3462069 | 0.71 | CD44 (0.65) | SMN1; SMN2CD44DPP4CYP3A4TDP1 | |
| SCHEMBL30136797 | 0.70 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNATSHRALDH1A1KDM4E | |
| SCHEMBL584175 | 0.70 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNATSHRALDH1A1KDM4E | |
| SCHEMBL3348708 | 0.70 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNACYP3A4TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389373-B1 | DERIVATIVES OF N2-(3-PYRIDYL OR PHENYL)-N4-(4-PIPERIDYL)-2,4-PYRIMIDINEDIAMINE USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE OR PROLIFERATIVE DISEASES | RIGEL PHARMACEUTICALS INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9149475-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20130210810-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8377924-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2389373-A1 | DERIVATIVES OF N2-(3-PYRIDIL OR PHENYL)-N4-(4-PIPERIDYL)-2,4-PYRIMIDINEDIAMINE USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE OR PROLIFERATIVE DISEASES | Rigel Pharmaceuticals, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110253835-A1 | AIRCRAFT INTERIOR LAVATORY | BE INTELLECTUAL PROPERTY, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2010090875-A1 | DERIVATIVES OF N2-(3-PYRIDIL OR PHENYL)-N4-(4-PIPERIDYL)-2,4-PYRIMIDINEDIAMINE USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE OR PROLIFERATIVE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | SMN1; SMN2 1709/4885CD44 3900/4885LMNA 892/4885 |
| US-20130210810-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | SMN1; SMN2 1709/4885CD44 3900/4885LMNA 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.